Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100
Debt
Debt-to-Equity RatioN/A
Current Ratio5.02
Quick Ratio5.02
Price-To-Earnings
Trailing P/E Ratio-10.98
Forward P/E Ratio-8.50
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.44 million
Price / Sales167.41
Cash FlowN/A
Price / CashN/A
Book Value$1.04 per share
Price / Book6.87
Profitability
EPS (Most Recent Fiscal Year)($0.65)
Net Income$-32,420,000.00
Net MarginsN/A
Return on Equity-78.61%
Return on Assets-65.55%
Miscellaneous
Employees47
Outstanding Shares57,210,000
Market Cap$414.74 million
Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions
What is Corbus Pharmaceuticals' stock symbol?
Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals' earnings last quarter?
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The biopharmaceutical company had revenue of $0.85 million for the quarter, compared to the consensus estimate of $1.90 million. View Corbus Pharmaceuticals' Earnings History.
When is Corbus Pharmaceuticals' next earnings date?
What price target have analysts set for CRBP?
3 brokers have issued 1 year price objectives for Corbus Pharmaceuticals' stock. Their predictions range from $20.00 to $36.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $26.6667 in the next twelve months. This suggests a possible upside of 267.8% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.
What is the consensus analysts' recommendation for Corbus Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.
Who are some of Corbus Pharmaceuticals' key competitors?
Some companies that are related to Corbus Pharmaceuticals include Endocyte (ECYT), Theravance Biopharma (TBPH), Puma Biotechnology (PBYI), Innoviva (INVA), Aimmune Therapeutics (AIMT), G1 Therapeutics (GTHX), Enanta Pharmaceuticals (ENTA), ARMO Biosciences (ARMO), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Corcept Therapeutics (CORT), Biohaven Pharmaceutical (BHVN), Spectrum Pharmaceuticals (SPPI) and Wave Life Sciences (WVE).
Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the folowing people:
- Dr. Yuval Cohen, CEO & Director (Age 43)
- Dr. Mark A. Tepper, Co-Founder, Pres & Chief Scientific Officer (Age 61)
- Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 60)
- Dr. Barbara White, Chief Medical Officer (Age 68)
- Ted Jenkins, Sr. Director of Investor Relations & Communications
Who are Corbus Pharmaceuticals' major shareholders?
Corbus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.16%). Company insiders that own Corbus Pharmaceuticals stock include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.
Which institutional investors are buying Corbus Pharmaceuticals stock?
CRBP stock was acquired by a variety of institutional investors in the last quarter, including Woodstock Corp. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.
How do I buy shares of Corbus Pharmaceuticals?
Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals' stock price today?
One share of CRBP stock can currently be purchased for approximately $7.25.
How big of a company is Corbus Pharmaceuticals?
Corbus Pharmaceuticals has a market capitalization of $414.74 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.
What is Corbus Pharmaceuticals' official website?
How can I contact Corbus Pharmaceuticals?
Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]
MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
